Loading clinical trials...

UNKNOWNNA

Zero-ischemia Robot-assisted Partial Nephrectomy Using Near-infrared Fluorescence

Zero-ischemia Robot-assisted Partial Nephrectomy Using Near-infrared Fluorescence: A Prospective, Monocentric, Randomized, Comparative and Open-label Study

NCT03679572•University Hospital, Grenoble

View on ClinicalTrials.gov

Summary

Patients with renal cancer are commonly treated by robot-assisted partial nephrectomy. Renal artery clamping is commonly required inducing kidney ischemia during surgery. It impacts parenchymal and renal function. This study aims to compare a new surgical procedure in order to reduce ischemia effect and preserve renal function after partial nephrectomy for renal tumour.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•candidate for a robot-assisted partial nephrectomy for renal tumour
•patient affiliated to social security
•signature of the informed consent

Exclusion Criteria

•proven or suspected allergy to the indocyanine green
•coagulation disorder contraindicating robot assistance in the partial nephrectomy
•medical pathology contraindicating pneumo-peritoneum
•multiple tumors
•horseshoe kidney
•exclusion period of another interventionnal study
•protected person referred to in Articles L1121-5 to L1121-8 of the Code of Public Health

Locations (1)

University Hospital Grenoble-Alps (CHU-GA)

La Tronche, France

Key Dates

Start Date

February 5, 2018

Primary Completion Date

February 10, 2020

Completion Date

December 1, 2020

Last Updated

March 18, 2020

Enrollment

ACTUAL participants

Conditions

Renal Cancer

Interventions

Robot assisted partial nephrectomy super-selective clamping

PROCEDURE

Robot assisted partial nephrectomy with renal artery clamping

PROCEDURE

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

RECRUITINGPHASE1/PHASE2

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415

Carcinoma, Renal CellAdvanced Renal Cell Carcinoma+11 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Zero-ischemia Robot-assisted Partial Nephrectomy Using Near-infrared Fluorescence

Inclusion Criteria

Exclusion Criteria

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Video Education With Result Dependent dIsclosure

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

Stereotactic Magnetic Resonance Guided Radiation Therapy

Planning Operative Strategy Using a Digital Renal Artery Clamping Tool